Role of the microbiome, probiotics, and 'dysbiosis therapy' in critical illness

Current Opinion in Critical Care

Volumn 22, Issue 4, 2016, Pages 347-353

  Wischmeyer, Paul E ^a   McDonald, Daniel ^b   Knight, Rob ^c  

^a UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^b INSTITUTE FOR SYSTEMS BIOLOGY   (United States)

^c UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

Author keywords

antibiotics; bacteria; critical care; fecal transplant; infection

Indexed keywords

PREBIOTIC AGENT; PROBIOTIC AGENT;

ANTIBIOTIC THERAPY; CRITICAL ILLNESS; DYSBIOSIS; FECAL MICROBIOTA TRANSPLANTATION; HUMAN; INFECTION; INFECTION PREVENTION; INTENSIVE CARE UNIT; INTESTINE FLORA; MULTIPLE ORGAN FAILURE; OUTCOME ASSESSMENT; PEPTOCLOSTRIDIUM DIFFICILE; REVIEW; SEPSIS; TREATMENT INDICATION; CROSS INFECTION; MICROFLORA;

CRITICAL ILLNESS; CROSS INFECTION; DYSBIOSIS; HUMANS; INTENSIVE CARE UNITS; MICROBIOTA; PROBIOTICS;

EID: 84975217570     PISSN: 10705295     EISSN: 15317072     Source Type: Journal    
DOI: 10.1097/MCC.0000000000000321     Document Type: Review

References (35)

1. Vincent JL, Rello J, Marshall J, et al. International study of the prevalence and outcomes of infection in intensive care units. JAMA 2009; 302:2323-2329.
2. Singer M, Glynne P. Treating critical illness: the importance of first doing no harm. PLoS Med 2005; 2:e167.
3. Ruttimann S, Keck B, Hartmeier C, et al. Long-term antibiotic cost savings from a comprehensive intervention program in a medical department of a university-affiliated teaching hospital. Clin Infect Dis 2004; 38:348-356.
4. Fridkin S, Baggs J, Fagan R, et al. Vital signs: improving antibiotic use among hospitalized patients. MMWR Morb Mortal Wkly Rep 2014; 63:194-200.
5. Lessa FC, Mu Y, Bamberg WM, et al. Burden of Clostridium difficile infection in the United States. N Engl J Med 2015; 372:825-834.
6. Rello J, Quintana E, Ausina V, et al. A three-year study of severe communityacquired pneumonia with emphasis on outcome. Chest 1993; 103:232-235.
7. Milbrandt EB, Kersten A, Rahim MT, et al. Growth of intensive care unit resource use and its estimated cost in Medicare. Crit Care Med 2008; 36:2504-2510.
8. Klingensmith NJ, Coopersmith CM. The gut as the motor of multiple organ dysfunction in critical illness. Crit Care Clin 2016; 32:203-212.
9. Broquet A, Roquilly A, Jacqueline C, et al. Depletion of natural killer cells increases mice susceptibility in a Pseudomonas aeruginosa pneumonia model. Crit Care Med 2014; 42:e441-e450.
10. Khailova L, Baird CH, Rush AA, et al. Lactobacillus rhamnosus GG improves outcome in experimental Pseudomonas aeruginosa pneumonia: potential role of regulatory T cells. Shock 2013; 40:496-503.
11. Gupta S, Allen-Vercoe E, Petrof EO. Fecal microbiota transplantation: in perspective. Therap Adv Gastroenterol 2016; 9:229-239.
12. Locey KJ, Lennon JT. Scaling laws predict global microbial diversity. Proc Natl Acad Sci U S A 2016; 113:5970-5975.
13. Sender R, Fuchs S, Milo R. Are we really vastly outnumbered? Revisiting the ratio of bacterial to host cells in humans. Cell 2016; 164:337-340.
14. Lozupone CA, Stombaugh JI, Gordon JI, et al. Diversity, stability and resilience of the human gut microbiota. Nature 2012; 489:220-230.
15. Dickson RP. The microbiome and critical illness. Lancet Respir Med 2016; 4:59-72.
16. Marini JJ, Gattinoni L, Ince C, et al. A few of our favorite unconfirmed ideas. Crit Care 2015; 19 (Suppl 3):S1.
17. Andrade ME, Araujo RS, de Barros PA, et al. The role of immunomodulators on intestinal barrier homeostasis in experimental models. Clin Nutr 2015; 34:1080-1087.
18. Krezalek MA, DeFazio J, Zaborina O, et al. The shift of an intestinal ''microbiome'' to a ''pathobiome'' governs the course and outcome of sepsis following surgical injury. Shock 2016; 45:475-482.
19. Khailova L, Petrie B, Baird CH, et al. Lactobacillus rhamnosus GG and Bifidobacterium longum attenuate lung injury and inflammatory response in experimental sepsis. PLoS One 2014; 9:e97861.
20. Shimizu K, Ogura H, Asahara T, et al. Probiotic/synbiotic therapy for treating critically ill patients from a gut microbiota perspective. Dig Dis Sci 2013; 58:23-32.
21. Petrof EO, Dhaliwal R, Manzanares W, et al. Probiotics in the critically ill: a systematic review of the randomized trial evidence. Crit Care Med 2012; 40:3290-3302.
22. Siempos II, Ntaidou TK, Falagas ME. Impact of the administration of probiotics on the incidence of ventilator-associated pneumonia: a meta-analysis of randomized controlled trials. Crit Care Med 2010; 38:954-962.
23. Barraud D, Bollaert PE, Gibot S. Impact of the administration of probiotics on mortality in critically ill adult patients: a meta-analysis of randomized controlled trials. Chest 2013; 143:646-655.
24. Wang J, Liu KX, Ariani F, et al. Probiotics for preventing ventilator-associated pneumonia: a systematic review and meta-analysis of high-quality randomized controlled trials. PLoS One 2013; 8:e83934.
25. Bo L, Li J, Tao T, et al. Probiotics for preventing ventilator-associated pneumonia. Cochrane Database Syst Rev 2014; 10:CD009066.
26. Rongrungruang Y, Krajangwittaya D, Pholtawornkulchai K, et al. Randomized controlled study of probiotics containing Lactobacillus casei (Shirota strain) for prevention of ventilator-associated pneumonia. J Med Assoc Thai 2015; 98:253-259.
27. Zeng J, Wang CT, Zhang FS, et al. Effect of probiotics on the incidence of ventilator-associated pneumonia in critically ill patients: a randomized controlled multicenter trial. Intensive Care Med 2016; 42:1018-1028.
28. Hempel S, Newberry SJ, Maher AR, et al. Probiotics for the prevention and treatment of antibiotic-associated diarrhea: a systematic review and metaanalysis. JAMA 2012; 307:1959-1969.
29. Goldenberg JZ, Ma SS, Saxton JD, et al. Probiotics for the prevention of clostridium difficile-associated diarrhea in adults and children. Cochrane Database Syst Rev 2013; 5:CD006095.
30. Kassam Z, Lee CH, Yuan Y, Hunt RH. Fecal microbiota transplantation for Clostridium difficile infection: systematic review and meta-analysis. Am J Gastroenterol 2013; 108:500-508.
31. Zaborin A, Smith D, Garfield K, et al. Membership and behavior of ultra-lowdiversity pathogen communities present in the gut of humans during prolonged critical illness. MBio 2014; 5:e01361-e1414.
32. Ojima M, Motooka D, Shimizu K, et al. Metagenomic analysis reveals dynamic changes of whole gut microbiota in the acute phase of intensive care unit patients. Dig Dis Sci 2016; 61:1628-1634.
33. Lyons JD, Ford ML, Coopersmith CM. The microbiome in critical illness: firm conclusions or Bact to square one? Dig Dis Sci 2016; 61:1420-1421.
34. Wischmeyer P, McDonald D, Heyland DK, et al. Abstract 10: ICU microbiome project: critical illness is associated with loss of microbial diversity and major alterations in bacterial flora. JPEN J Parenter Enteral Nutr 2016; 40:123.
35. Sokol H, Pigneur B, Watterlot L, et al. Faecalibacterium prausnitzii is an antiinflammatory commensal bacterium identified by gut microbiota analysis of Crohn disease patients. Proc Natl Acad Sci U S A 2008; 105:16731-16736.